Last updated: August 2, 2026
TERAZOL 3 is a mature prescription vaginal antifungal containing terconazole 80 mg in a three-day suppository regimen. Its commercial position is driven by generic substitution, low-cost alternatives, and limited differentiation from other azole antifungals. The product has no visible characteristics of a growth-stage pharmaceutical asset: public filings do not disclose standalone brand revenue, active patent exclusivity, major licensing transactions, or current brand-specific clinical expansion.
The financial opportunity is concentrated in the broader terconazole and vulvovaginal candidiasis market rather than in TERAZOL 3 as a protected brand.
What is TERAZOL 3 and how does it work?
TERAZOL 3 is an intravaginal formulation of terconazole, a triazole antifungal used for the local treatment of vulvovaginal candidiasis. Each vaginal suppository contains 80 mg of terconazole and is administered once daily for three consecutive days.[1]
Terconazole inhibits fungal sterol synthesis by interfering with lanosterol 14-alpha-demethylase. The resulting disruption of ergosterol production damages the fungal cell membrane. The product is intended for vaginal administration and is not an oral systemic antifungal.
| Product attribute |
TERAZOL 3 |
| Active ingredient |
Terconazole |
| Strength |
80 mg per vaginal suppository |
| Dosage form |
Vaginal suppository |
| Standard regimen |
One suppository daily for three days |
| Primary indication |
Vulvovaginal candidiasis |
| Regulatory category |
Prescription drug |
| Therapeutic class |
Vaginal azole antifungal |
| Main competitors |
Generic terconazole, miconazole, clotrimazole, oral fluconazole |
| Biosimilar relevance |
None |
The three-day regimen gives TERAZOL 3 a shorter treatment duration than some seven-day topical regimens. It competes on route of administration, tolerability, prescriber familiarity, and availability rather than on patent-protected clinical differentiation.
What is the FDA regulatory status of TERAZOL 3?
TERAZOL 3 has an established FDA regulatory history as a terconazole vaginal product. The FDA-approved labeling identifies the product as a prescription treatment for vulvovaginal candidiasis and provides dosing, contraindications, warnings, and patient-use instructions.[1]
The FDA label directs patients to avoid intercourse and other vaginal products during treatment where applicable. The product is not indicated for systemic fungal infections or for treatment of sexually transmitted infections.
The regulatory position is commercially mature:
| Regulatory factor |
Assessment |
| FDA approval pathway |
Established NDA product history |
| Current prescription status |
Prescription |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No material current impact identified |
| Orphan-drug exclusivity |
Not applicable |
| OTC switch |
No established TERAZOL 3 switch identified |
| Generic competition |
Present at the active-ingredient and dosage-form level |
The product’s regulatory value is therefore based on market recognition and manufacturing availability, not remaining FDA exclusivity.
When did TERAZOL 3 lose exclusivity?
TERAZOL 3 is a legacy product, and any original new-drug exclusivity or early brand protection has expired. The commercial market includes generic terconazole products, which eliminates the economic conditions associated with a protected single-source product.
A precise current patent-expiration date should not be assigned to TERAZOL 3 without identifying the relevant historical NDA, patent listings, and any later formulation or manufacturing patents. The FDA label and public regulatory materials establish the product’s approved composition and use, but they do not by themselves establish an active, enforceable patent barrier.[1,2]
Does TERAZOL 3 have active Orange Book patents?
The commercial significance of Orange Book protection appears limited. TERAZOL 3 is an established product with generic competition, and no active exclusivity period is associated with the product in the cited FDA materials.
Orange Book analysis must distinguish among:
- The original terconazole compound.
- The 80 mg vaginal suppository formulation.
- Manufacturing processes.
- Method-of-use claims.
- Device or applicator claims, if any.
- Patents associated with a particular manufacturer’s generic product.
A generic terconazole approval does not necessarily establish that every historical patent has expired. It does show that FDA approval proceeded through an abbreviated regulatory pathway or another route that permitted market access. Patent status must be assessed patent by patent using the relevant Orange Book edition, FDA listing history, and court records.[2]
How many patents cover TERAZOL 3?
No reliable standalone patent count can be derived from the product name alone. TERAZOL 3 is a brand designation for a terconazole dosage form, while patent families may use the active ingredient, formulation, treatment method, or manufacturing process in their titles.
The practical patent position is weak relative to newer branded medicines for four reasons:
- Terconazole is an established active ingredient.
- The three-day vaginal regimen is commercially mature.
- Generic products are available.
- No current patent litigation or settlement structure is publicly associated with the product in the cited sources.
The likely remaining barriers, if any, would relate to formulation process controls, excipient composition, manufacturing yield, packaging, or supplier qualification. Those barriers can raise launch costs without creating meaningful market exclusivity.
What generic entry risks exist for TERAZOL 3?
Generic substitution is the primary market risk. Generic terconazole products can compete directly on the same active ingredient, strength, route, and treatment duration. Pharmacies and payers generally have incentives to substitute lower-priced products unless a prescriber or patient prefers the branded product.
Competitive pressure comes from two directions.
Direct generic competition
Generic terconazole vaginal suppositories are the closest substitutes. They target the same diagnosis and offer the same basic treatment regimen. Price, wholesaler availability, and payer formulary position are the main commercial variables.
Therapeutic substitution
TERAZOL 3 also competes with:
- Miconazole vaginal creams and suppositories.
- Clotrimazole vaginal products.
- Oral fluconazole.
- Longer-course topical azole regimens.
- Lower-cost store-brand vaginal antifungals.
Oral fluconazole has a different route and prescribing profile but can be a strong substitute for uncomplicated vulvovaginal candidiasis. Topical miconazole and clotrimazole compete more directly for patients and clinicians prioritizing local treatment.
Which companies are challenging TERAZOL 3?
Generic-drug manufacturers and private-label distributors are the relevant competitive group. The market is not characterized by a high-profile branded challenger or an identified Paragraph IV campaign.
No significant public Paragraph IV litigation involving TERAZOL 3 is identified in the cited FDA materials. That outcome is consistent with a mature product where market entry can occur through established generic pathways and where the remaining commercial value does not justify extensive patent litigation.
Potential competitors include manufacturers that produce or distribute generic terconazole vaginal products, as well as companies selling competing vaginal azoles. The identity of the applicant can vary by dosage form, labeler, contract manufacturer, and distributor.
What patent litigation affects TERAZOL 3?
No material current patent litigation affecting TERAZOL 3 is identified in the cited public regulatory record. The product does not appear to have the litigation profile of high-value branded drugs with active composition-of-matter or formulation patents.
The principal litigation risks would be commercial rather than exclusivity-driven:
| Risk category |
Relevance to TERAZOL 3 |
| Paragraph IV challenge |
Low visible significance |
| Patent-infringement suit |
No material current case identified |
| Trade-secret dispute |
Possible at the manufacturing level, not established |
| Trademark dispute |
Possible for branding and packaging |
| Product liability |
General pharmaceutical risk |
| Antitrust or pay-for-delay case |
No identified current settlement structure |
A generic launch would more likely be determined by FDA approval, manufacturing readiness, wholesaler access, and payer substitution than by a publicly visible patent trial.
What formulations are protected by TERAZOL 3?
The commercial formulation is an 80 mg terconazole vaginal suppository administered over three days. The formulation’s practical differentiation lies in the dosage form and regimen rather than in a novel delivery technology.
Potential formulation attributes include:
- Suppository base composition.
- Terconazole particle size and dispersion.
- Drug-release characteristics.
- Stability under temperature variation.
- Packaging and storage conditions.
- Manufacturing controls for content uniformity.
- Compatibility with vaginal administration.
These attributes can be difficult to reproduce at scale, but they do not necessarily create enforceable market exclusivity. A generic manufacturer can obtain approval by demonstrating pharmaceutical equivalence and bioequivalence or by satisfying the applicable FDA requirements for the dosage form.[3]
No evidence establishes that TERAZOL 3 currently benefits from a proprietary controlled-release system, patented applicator, or differentiated delivery platform.
How strong is the TERAZOL 3 patent estate?
The patent estate is commercially weak to moderate, depending on the specific manufacturer and jurisdiction. It is weak as a source of brand-level exclusivity because the active ingredient and dosage form are established and generic competition exists.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired or commercially irrelevant |
| Formulation protection |
Limited visible significance |
| Method-of-use protection |
Low practical barrier |
| Manufacturing patents |
Potentially relevant to cost and supply |
| Orange Book leverage |
Limited |
| Generic litigation leverage |
Low |
| Geographic variation |
Possible outside the United States |
| Overall exclusivity strength |
Low |
Manufacturing know-how may still have value. Producing a stable vaginal suppository at competitive cost requires control of raw-material quality, melting behavior, filling, cooling, packaging, and shelf-life performance. These capabilities can protect margins operationally, but they do not prevent competitors from entering the market.
What is the financial trajectory of TERAZOL 3?
Standalone TERAZOL 3 revenue is not publicly reported in the cited company or FDA materials. The product should therefore be analyzed as a mature, low-growth prescription brand or genericized product rather than as an individually disclosed revenue asset.
The likely financial trajectory has four phases:
| Period |
Financial profile |
| Launch and early adoption |
Brand-supported growth from clinical adoption |
| Patent and exclusivity period |
Higher pricing and stronger gross margins |
| Generic entry |
Rapid price compression and share migration |
| Mature market |
Stable or declining revenue, dependent on distribution and supply |
Brand revenue typically contracts after generic entry because pharmacies substitute approved generic equivalents and payers impose lower reimbursement. Residual branded demand may persist among prescribers, patients, or channels that retain the brand, but the revenue pool is usually smaller and less defensible.
The most relevant financial metrics are:
- Net sales by labeler.
- Prescription volume.
- Generic substitution rate.
- Average selling price.
- Gross-to-net deductions.
- Wholesaler inventory.
- Formulary position.
- Manufacturing cost per suppository.
- Product availability and back-order frequency.
TERAZOL 3’s financial upside is more likely to come from efficient manufacturing, reliable supply, private-label distribution, and portfolio bundling than from price increases or new indications.
What licensing deals involve TERAZOL 3?
No major publicly disclosed licensing transaction involving TERAZOL 3 is identified in the cited sources. A legacy product can move between brand owners, authorized distributors, contract manufacturers, or pharmaceutical portfolios without generating a separately reported transaction value.
Potential commercial arrangements include:
- Authorized-generic distribution.
- Contract manufacturing.
- Private-label supply.
- Portfolio acquisition.
- Regional commercialization rights.
- Wholesale distribution agreements.
The absence of a visible licensing transaction supports the view that TERAZOL 3 is a maintenance product rather than a strategic licensing asset with substantial remaining exclusivity.
How does TERAZOL 3 compare with competing antifungals?
| Product |
Route |
Typical positioning |
Competitive pressure |
| TERAZOL 3 |
Vaginal suppository |
Three-day local terconazole treatment |
High from generic terconazole |
| Generic terconazole cream |
Vaginal |
Same active ingredient, different dosage form |
High |
| Miconazole |
Vaginal |
Widely available topical treatment |
High |
| Clotrimazole |
Vaginal |
Established topical azole |
Moderate to high |
| Fluconazole |
Oral |
Convenient systemic treatment |
High therapeutic substitution |
TERAZOL 3’s main advantages are its short local-treatment regimen and established clinical familiarity. Its disadvantages are generic price competition, limited brand differentiation, and competition from an oral single-dose option in appropriate patients.
What generic launch scenarios exist for TERAZOL 3?
The most likely scenarios are:
- Generic maintenance competition continues, with price erosion and stable demand.
- A supply disruption at one manufacturer increases short-term pricing power for remaining suppliers.
- Private-label products expand through retail and pharmacy channels.
- Prescribers shift toward oral fluconazole or other topical azoles.
- The brand remains available but becomes commercially marginal.
A successful generic launch requires FDA approval, qualified manufacturing, stable active-ingredient supply, validated suppository production, packaging compliance, and wholesaler access. Patent litigation is unlikely to be the central launch constraint based on the available public record.
What is the geographic coverage of TERAZOL 3?
TERAZOL 3 is primarily relevant to the United States prescription market. Terconazole products may be marketed in other countries under different brand names, strengths, formulations, or regulatory classifications.
International commercial analysis must account for:
- Country-specific approval status.
- Different treatment guidelines.
- Local generic manufacturers.
- Prescription versus pharmacy status.
- Reimbursement systems.
- Trademark ownership.
- Patent and supplementary-protection rules.
- Import and manufacturing requirements.
A U.S. product assessment should not be treated as a global exclusivity assessment. Geographic patent coverage and commercial ownership can differ materially by country.
Key Takeaways
- TERAZOL 3 contains terconazole 80 mg in a three-day vaginal suppository regimen.
- It is a mature prescription antifungal with generic and therapeutic competition.
- Original exclusivity has expired, and current commercial value is not driven by a visible patent moat.
- No material current Paragraph IV litigation, settlement agreement, or major licensing transaction is identified in the cited public record.
- Generic terconazole, miconazole, clotrimazole, and oral fluconazole are the main competitive pressures.
- Standalone TERAZOL 3 revenue is not publicly disclosed.
- Future financial performance depends on supply reliability, manufacturing cost, distribution, payer substitution, and residual brand demand.
- The strongest remaining barriers are operational and manufacturing-related, not composition-of-matter or regulatory exclusivity barriers.
FAQs About TERAZOL 3 Market and Patent Status
Is TERAZOL 3 still a profitable product?
It can generate maintenance revenue for a manufacturer with efficient production and distribution, but its profitability is constrained by generic substitution and low differentiation. Public sources do not disclose standalone product profit.
Is terconazole available without a prescription?
TERAZOL 3 is an FDA prescription product. OTC status can differ for other vaginal antifungal products and should not be inferred from the availability of miconazole or clotrimazole products.
Does TERAZOL 3 have biosimilar competition?
No. Biosimilars apply to biological products. TERAZOL 3 is a small-molecule antifungal, so competition occurs through generic-drug pathways.
Can a generic manufacturer make a three-day terconazole suppository?
A manufacturer can seek FDA approval for a therapeutically equivalent product if it meets the applicable requirements for pharmaceutical equivalence, quality, manufacturing, labeling, and bioequivalence or other required evidence.[3]
Is TERAZOL 3 strategically attractive for pharmaceutical acquisition?
Its attractiveness would depend on manufacturing economics, supply reliability, portfolio fit, and distribution access. The product is unlikely to justify a high valuation based on patent exclusivity or strong standalone growth.
References
-
U.S. Food and Drug Administration. (n.d.). TERAZOL-3 (terconazole nitrate) vaginal suppository prescribing information. FDA labeling database.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023). Abbreviated new drug application process. U.S. Department of Health and Human Services.
